Skip to content

Opening book details…

Can I read Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata on EtoBox?

Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata by Yael Renert‐Yuval; Ana B. Pavel; Ester Del Duca; Paola Facheris; Angel D. Pagan; Swaroop Bose; Pedro J. Gómez‐Arias; Michael Angelov; Jennifer Bares; Margo Chima; Yeriel D. Estrada; Sandra Garcet; Mark G. Lebwohl; James G. Krueger; Emma Guttman‐Yassky is a Medicine article available to read on EtoBox.

What is Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata about?

## Abstract ## Background The mechanisms driving alopecia areata (AA) are still unclear, hindering development of targeted therapeutics. Specific Th2 targeting with dupilumab in AA provides a unique opportunity to dissect its pathogenesis and explore the role of Th2 pathway. ## Methods We evaluated changes in scalp biomarkers in AA patients (with and without concomitant atopy) randomized to weekly dupilumab or placebo for 24 weeks, followed by open‐label dupilumab for 24 weeks. Changes in biomarker levels were measured at weeks 12, 24, and 48 and were also correlated with clinical hair regrowth. ## Results At week 24, preceding clinical hair regrowth outcomes, only dupilumab‐treated patients presented significant suppression of cellular infiltrates, and multiple Th2‐related, markers (CCL13/MCP‐4, CCL18/PARC, CCL26/eotaxin‐3, CCL24/Eotaxin‐2), coupled with significant upregulation in the hair keratins. Th1‐related suppression was evident later (week 48) when all patients received open‐label dupilumab. Results were more pronounced in atopic AA patients, that showed 48% and 97% improvements in the lesional AA scalp profile at weeks 24 and 48, respectively, while 2% worsening was seen

Who reads Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Yael Renert‐Yuval; Ana B. Pavel; Ester Del Duca; Paola Facheris; Angel D. Pagan; Swaroop Bose; Pedro J. Gómez‐Arias; Michael Angelov; Jennifer Bares; Margo Chima; Yeriel D. Estrada; Sandra Garcet; Mark G. Lebwohl; James G. Krueger; Emma Guttman‐Yassky
Publisher
Wiley
Published
2022
Language
EN
Field
Medicine (Health Sciences)

More by Yael Renert‐Yuval; Ana B. Pavel; Ester Del Duca; Paola Facheris; Angel D. Pagan; Swaroop Bose; Pedro J. Gómez‐Arias; Michael Angelov; Jennifer Bares; Margo Chima; Yeriel D. Estrada; Sandra Garcet; Mark G. Lebwohl; James G. Krueger; Emma Guttman‐Yassky

Browse all works by Yael Renert‐Yuval; Ana B. Pavel; Ester Del Duca; Paola Facheris; Angel D. Pagan; Swaroop Bose; Pedro J. Gómez‐Arias; Michael Angelov; Jennifer Bares; Margo Chima; Yeriel D. Estrada; Sandra Garcet; Mark G. Lebwohl; James G. Krueger; Emma Guttman‐Yassky